Table 9: Survival with MARS Therapy Study Pathology Controlled Study Follow-up Survival (%) Faenza et al.[95] (2008) ACLF No Bridging to LTx 7/10 (70) 3 months 2/6 (33) Krisper et al.[96](2005) ACLF Yes (crossover) 30 days 4/9 (44) Stadlbauer et al.[97] (2006) ACLF Yes (crossover) 30 days 4/8 (50) Laleman et al.[55]'(2006) ACLF Yes 7 days 6/6 (100) Dethloff et al..'[59]'(2008) ESLD Yes 6 months 5/8 (63)